196 related articles for article (PubMed ID: 37640446)
1. Evolving treatment paradigms in metastatic or recurrent low-grade endometrial cancer: When is hormonal-based therapy the preferred option?
Mahdi H; Ray-Coquard I; Lorusso D; Mirza MR; Monk BJ; Slomovitz B
Int J Gynecol Cancer; 2023 Nov; 33(11):1675-1681. PubMed ID: 37640446
[TBL] [Abstract][Full Text] [Related]
2. The promise of combining CDK4/6 inhibition with hormonal therapy in the first-line treatment setting for metastatic or recurrent endometrial adenocarcinoma.
Ray-Coquard I; Monk BJ; Lorusso D; Mahdi H; Upadhyay V; Graul R; Husain A; Mirza MR; Slomovitz B
Int J Gynecol Cancer; 2023 Dec; 33(12):1943-1949. PubMed ID: 37907262
[TBL] [Abstract][Full Text] [Related]
3. Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: Hormonal therapy, chemotherapy and molecularly targeted therapies.
Gadducci A; Cosio S; Genazzani AR
Crit Rev Oncol Hematol; 2006 Jun; 58(3):242-56. PubMed ID: 16436330
[TBL] [Abstract][Full Text] [Related]
4. Durable response in a woman with recurrent low-grade endometrioid endometrial cancer and a germline BRCA2 mutation treated with a PARP inhibitor.
Gockley AA; Kolin DL; Awtrey CS; Lindeman NI; Matulonis UA; Konstantinopoulos PA
Gynecol Oncol; 2018 Aug; 150(2):219-226. PubMed ID: 29937315
[TBL] [Abstract][Full Text] [Related]
5. Impact of hormonal biomarkers on response to hormonal therapy in advanced and recurrent endometrial cancer.
van Weelden WJ; Lalisang RI; Bulten J; Lindemann K; van Beekhuizen HJ; Trum H; Boll D; Werner HMJ; van Lonkhuijzen LRCW; Yigit R; Forsse D; Witteveen PO; Galaal K; van Ginkel A; Bignotti E; Weinberger V; Sweegers S; Kroep JR; Cabrera S; Snijders MPLM; Inda MA; Eriksson AGZ; ; Krakstad C; Romano A; van de Stolpe A; Pijnenborg JMA
Am J Obstet Gynecol; 2021 Oct; 225(4):407.e1-407.e16. PubMed ID: 34019887
[TBL] [Abstract][Full Text] [Related]
6. An intensive follow-up does not change survival of patients with clinical stage I endometrial cancer.
Gadducci A; Cosio S; Fanucchi A; Cristofani R; Genazzani AR
Anticancer Res; 2000; 20(3B):1977-84. PubMed ID: 10928137
[TBL] [Abstract][Full Text] [Related]
7. Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer.
Tsoref D; Welch S; Lau S; Biagi J; Tonkin K; Martin LA; Ellard S; Ghatage P; Elit L; Mackay HJ; Allo G; Tsao MS; Kamel-Reid S; Eisenhauer EA; Oza AM
Gynecol Oncol; 2014 Nov; 135(2):184-9. PubMed ID: 25173583
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma.
Soslow RA; Wethington SL; Cesari M; Chiappetta D; Olvera N; Shia J; Levine DA
Am J Surg Pathol; 2012 Dec; 36(12):1771-81. PubMed ID: 23154767
[TBL] [Abstract][Full Text] [Related]
9. Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: a stratified type I-type II study from the GINECO group.
Heudel PE; Fabbro M; Roemer-Becuwe C; Kaminsky MC; Arnaud A; Joly F; Roche-Forestier S; Meunier J; Foa C; You B; Priou F; Tazi Y; Floquet A; Selle F; Berton-Rigaud D; Lesoin A; Kalbacher E; Lortholary A; Favier L; Treilleux I; Ray-Coquard I
Br J Cancer; 2017 Jan; 116(3):303-309. PubMed ID: 28072765
[TBL] [Abstract][Full Text] [Related]
10. SPECIFICITIES OF ENDOMETRIAL PROLIFERATION/STEM CELL INDEX DISTRIBUTION IN ENDOMETRIOID CARCINOMA OF DIFFERENT GRADE OF MALIGNANCY.
Kikalishvili N; Beriashvili R; Muzashvili T; Burkadze G
Georgian Med News; 2018 Mar; (276):117-123. PubMed ID: 29697394
[TBL] [Abstract][Full Text] [Related]
11. Recurrent endometrial cancer.
Del Carmen MG; Boruta DM; Schorge JO
Clin Obstet Gynecol; 2011 Jun; 54(2):266-77. PubMed ID: 21508696
[TBL] [Abstract][Full Text] [Related]
12. Systemic therapy in metastatic or recurrent endometrial cancer.
Pectasides D; Pectasides E; Economopoulos T
Cancer Treat Rev; 2007 Apr; 33(2):177-90. PubMed ID: 17196749
[TBL] [Abstract][Full Text] [Related]
13. Coexistence of endometrial mesonephric-like adenocarcinoma and endometrioid carcinoma suggests a Müllerian duct lineage: a case report.
Yano M; Shintani D; Katoh T; Hamada M; Ito K; Kozawa E; Hasegawa K; Yasuda M
Diagn Pathol; 2019 Jun; 14(1):54. PubMed ID: 31174566
[TBL] [Abstract][Full Text] [Related]
14. A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: a gynecologic oncology group study.
Tait DL; Blessing JA; Hoffman JS; Moore KN; Spirtos NM; Lachance JA; Rotmensch J; Miller DS
Gynecol Oncol; 2011 Apr; 121(1):118-21. PubMed ID: 21159366
[TBL] [Abstract][Full Text] [Related]
15. Phase 2 trial of mifepristone (RU-486) in advanced or recurrent endometrioid adenocarcinoma or low-grade endometrial stromal sarcoma.
Ramondetta LM; Johnson AJ; Sun CC; Atkinson N; Smith JA; Jung MS; Broaddus R; Iyer RB; Burke T
Cancer; 2009 May; 115(9):1867-74. PubMed ID: 19241422
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of high-dose progestin and long-term outcomes in young women with early-stage, well-differentiated endometrioid adenocarcinoma of uterine endometrium.
Park H; Seok JM; Yoon BS; Seong SJ; Kim JY; Shim JY; Park CT
Arch Gynecol Obstet; 2012 Feb; 285(2):473-8. PubMed ID: 21706284
[TBL] [Abstract][Full Text] [Related]
17. Comparable outcome between endometrioid and non-endometrioid tumors in patients with early-stage high-grade endometrial cancer.
Reynaers EA; Ezendam NP; Pijnenborg JM
J Surg Oncol; 2015 May; 111(6):790-4. PubMed ID: 25900897
[TBL] [Abstract][Full Text] [Related]
18. Antiangiogenic agents in advanced, persistent or recurrent endometrial cancer: a novel treatment option.
Gadducci A; Sergiampietri C; Guiggi I
Gynecol Endocrinol; 2013 Sep; 29(9):811-6. PubMed ID: 23767831
[TBL] [Abstract][Full Text] [Related]
19. Molecular markers in recurrent stage I, grade 1 endometrioid endometrial cancers.
Moroney MR; Davies KD; Wilberger AC; Sheeder J; Post MD; Berning AA; Fisher C; Lefkowits C; Guntupalli SR; Behbakht K; Corr BR
Gynecol Oncol; 2019 Jun; 153(3):517-520. PubMed ID: 30910249
[TBL] [Abstract][Full Text] [Related]
20. A phase II trial of carboplatin and docetaxel followed by radiotherapy given in a "Sandwich" method for stage III, IV, and recurrent endometrial cancer.
Geller MA; Ivy JJ; Ghebre R; Downs LS; Judson PL; Carson LF; Jonson AL; Dusenbery K; Vogel RI; Boente MP; Argenta PA
Gynecol Oncol; 2011 Apr; 121(1):112-7. PubMed ID: 21239048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]